CAS 2222844-89-3

AZD-9833

CAS : 2222844-89-3

Formule : C₂₄H₂₈F₄N₆

Degré de pureté : 99%

Couleur et forme : Solid

Masse moléculaire : 476.5129

Ref: IN-DA01V74F

Camizestrant

CAS : 2222844-89-3

Camizestrant

Degré de pureté : ≥95%

Masse moléculaire : 476.51g/mol

Ref: 54-BUP09142

AZD9833

CAS : 2222844-89-3

AZD9833 is an oral selective estrogen receptor degrader (SERD), which is a small molecule therapeutic synthesized by AstraZeneca. Its mode of action involves binding to the estrogen receptor, leading to the receptor's conformational change and subsequent degradation. This mechanism significantly downregulates estrogen receptor signaling, which is a crucial pathway in the progression of estrogen receptor-positive breast cancers.

Formule : C₂₄H₂₈F₄N₆

Degré de pureté : Min. 95%

Couleur et forme : Powder

Masse moléculaire : 476.23 g/mol

Ref: 3D-BA179501

Camizestrant

CAS : 2222844-89-3

Camizestrant (Estrogen receptor antagonist 2) is an antagonist of the estrogen receptor and can be used in studies about ER+ HER2-advanced breast cancer[1].

Formule : C₂₄H₂₈F₄N₆

Degré de pureté : 97.25% - 99.57%

Couleur et forme : Solid

Masse moléculaire : 476.51

Ref: TM-T11237